| Literature DB >> 35608709 |
Lea Gasser1, Sara Lener2, Sebastian Hartmann1, Wolfgang N Löscher3, Claudius Thomé1, Anja Hofer1.
Abstract
The importance of the type of pain medication in spinal disease is an ongoing matter of debate. Recent guidelines recommend acetaminophen and NSAIDs as first-line medication for lumbar disc herniation. However, opioid pain medication is commonly used in patients with chronic pain, and therefore also in patients with sciatica. The aim of this study is to evaluate if opioids have an impact on the outcome in patients suffering from lumbar disc herniation. To assess this objectively quantitative sensory testing (QST) was applied. In total, 52 patients with a single lumbar disc herniation confirmed on magnetic resonance imaging (MRI) and treated by lumbar sequesterectomy were included in the trial. Patients were analysed according to their preoperative opioid intake: 35 patients who did not receive opioids (group NO) and 17 patients, who received opioids preoperatively (group O). Further evaluation included detailed medical history, physical examination, various questionnaires, and QST. No pre- and postoperative differences were detected in thermal or mechanical thresholds (p > 0.05). Wind-up ratio (WUR) differed significantly between groups 1 week postoperatively (p = 0.025). The NRS for low back pain was rated significantly higher in the non-opioid group (NO) after 1-week follow-up (p = 0.026). Radicular pain tended to be higher in the NO group after 12 months of follow-up (p = 0.023). Opioids seem to be a positive predictor for the postoperative pain outcome in early follow-up in patients undergoing lumbar sequesterectomy. Furthermore, patients presented with less radicular pain 1 year after surgery.Entities:
Keywords: Lumbar disc herniation; Lumbar radiculopathy; Lumbar sequesterectomy; Opioid therapy; Quantitative sensory testing
Mesh:
Substances:
Year: 2022 PMID: 35608709 PMCID: PMC9349102 DOI: 10.1007/s10143-022-01818-z
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 2.800
Exclusion criteria
| Exclusion criteria |
Previous surgery at index level that caused a sensory nerve dysfunction Any degenerative muscular or neurological condition that would interfere with evaluation of outcome measures including but not limited to Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, and myelopathic diseases of different causes Participation in a clinical trial within the last 3 months Unable or unwilling to comply therapeutic instructions or to comply the follow-up visits at the study site Active or chronic infection, systemic or local, systemic disease including HIV, AIDS, hepatitis Active malignancy defined as a history of any invasive malignancy, except nonmelanoma skin cancer, unless the patient has been treated with curative intent and there have been no clinical unable to undergo MRI Neoplasia as the source of symptoms, diabetes mellitus Paget’s disease, osteomalacia, or any other metabolic bone disease. skin disease that influences sensory nerve function Polyneuropathy Autoimmune disorder that impacts the musculoskeletal system (i.e. lupus, rheumatoid arthritis, ankylosing spondylitis) Acute episode or major mental illness (psychosis, major affective disorder, or schizophrenia) and usage of antidepressive drugs Physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin Recent or current history of substance abuse (drugs, alcohol, narcotics, recreational drugs). Pursuing personal litigation related to spinal diseases Prisoner or ward of the state |
Demographic and clinical characteristics of 52 patients with single lumbar disc herniation
| Group NO, | Group O, | |||
|---|---|---|---|---|
| Demographic characteristics | ||||
| Female/male ratio | 16:19 | 05:12 | 0.266 | |
| Age | In years | 42 (± 4) | 47 (± 11) | 0.183 |
| BMI | In kg/m2 | 27 (± 4) | 25 (± 2) | 0.118 |
| Smoking, | 19 (54) | 10 (58) | 0.195 | |
| Cigarettes per day | 7 ± 9 | 7 ± 8 | 0.936 | |
| Alcohol | None, | 7 (20) | 6 (35) | 0.182 |
| Weekly, | 1 (2) | 1 (5) | ||
| Incidentally, | 27 (77) | 10 (58) | ||
| ASA score | 1, | 19 (54) | 12 (70) | 0.266 |
| 2, | 16 (45) | 5 (29) | ||
| Nerve root injection with steroid, | 7 (20) | 4 (23) | 0.772 | |
| Pain characteristics | ||||
| Passive leg raising test | Negative, | 9 (26) | 1 (5) | 0.092 |
| Positive, | 26 (74) | 16 (94) | ||
| Radicular pain | L3, n (%) | 2 (6) | 2 (11) | 0.192 |
| L4, | 3 (8) | 2 (11) | ||
| L5, | 16 (46) | 4 (23) | ||
| S1, | 14 (40) | 9 (52) | ||
| During of drug intake | In days ( | 27 (± 14) | 28 (± 14) | 0.881 |
Pain medication in the in the opioid group (O) and in the non-opioid group (NO)
| Group NO, | Group O, | |||
|---|---|---|---|---|
| sum | p.p | sum | p.p | |
| Antiepileptic drugs | ||||
| Gabapentin, mg/d | 1800 | 900 (2/35) | 1200 | 1200 (1/17) |
| Pregabalin, mg/d | 300 | 300 (1/35) | 0 | 0 (0/17) |
| Non-opioid analgetics | ||||
| Naproxen, mg/d | 1000 | 1000 (1/35) | 4000 | 1000 (4/17) |
| Metamizole, mg/dl | 2000 | 2000 (1/35) | 10.500 | 1750 (6/17) |
| Paracetamol, mg/d | 7500 | 1875 (4/35) | 8000 | 2000 (4/17) |
| Diclofenac, mg/d | 650 | 130 (5/35) | 100 | 100 (1/17) |
| Dexibuprofen, mg/d | 5000 | 1000 (5/35) | 4000 | 1000 (4/17) |
| Weak opioid analgetics | ||||
| Tramadol, mg/d | 0 | 0 (0/35) | 1800 | 180 (10/17) |
| Strong opioid analgetics | 0 (0/35) | |||
| Oxycodone, mg/d | 0 | 0 (0/35) | 65 | 21 (3/17) |
| Piritramid, mg/d | 0 | 0 (0/35) | 49.5 | 8.2 (6/17) |
Fig. 1Wind-up ratio (WUR) for group O and group NO preoperatively, 1 week, 6 months, and 12 months postoperatively
Fig. 2Numeric rating scale (NRS) for back and leg pain among group O and group NO preoperatively, 1 week, 6 months, and 12 months postoperatively
Questionnaire results: Oswestry disability index (ODI), core outcome measure index (COMI), Beck depression inventory (BDI), painDETECT questionnaire (PD-Q), EuroQol-5Dimension (EQ-5D) preoperatively, 1 week, 6 months, and 12 months postoperatively
| Questionnaire | Pre | 1w | 6 m | 12 m | Pre-12 m | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NO | O | p | NO | O | p | NO | O | p | NO | O | p | NO ∆p | O ∆p | |
| ODI sum | 33.0 ± 17 | 46.2 ± 15 | 24.0 ± 16 | 30.2 ± 17 | 0.214 | 8.6 ± 10 | 7.5 ± 8 | 0.725 | 8.6 ± 10 | 7.6 ± 8 | 0.745 | |||
| Pain intensity | 2.2 ± 1 | 3.1 ± 1 | 1.1 ± 0 | 0.9 ± 0 | 0.431 | 0.9 ± 0 | 0.6 ± 0 | 0.25 | 0.8 ± 0 | 0.5 ± 0 | 0.472 | |||
| Pain intensity | 0.7 ± 0 | 1.2 ± 0 | 0.6 ± 1 | 0.4 ± 0 | 0.752 | 0.1 ± 0 | 0.0 ± 0 | 0.691 | 0.1 ± 0 | 0.0 ± 0 | 0.639 | |||
| Lifting | 1.9 ± 1 | 2.5 ± 1 | 0.91 | 2.0 ± 1 | 3.4 ± 1 | 0.016 | 0.7 ± 0 | 0.6 ± 0 | 0.713 | 0.7 ± 0 | 1.0 ± 1 | 0.375 | ||
| Walking | 1.1 ± 1 | 1.8 ± 1 | 0.141 | 1.0 ± 1 | 1.1 ± 1 | 0.669 | 0.1 ± 0 | 0.0 ± 0 | 0.719 | 0.2 ± 0 | 0.1 ± 0 | 0.74 | ||
| Sitting | 1.7 ± 1 | 2.7 ± 1 | 1.6 ± 1 | 1.8 ± 1 | 0.501 | 0.6 ± 0 | 0.7 ± 1 | 0.829 | 0.6 ± 0 | 0.5 ± 0 | 0.956 | |||
| Standing | 2.2 ± 1 | 2.6 ± 1 | 0.376 | 1.7 ± 1 | 1.6 ± 1 | 0.846 | 0.5 ± 0 | 0.6 ± 0 | 0.611 | 0.6 ± 0 | 0.6 ± 0 | 0.761 | ||
| Sleeping | 1.3 ± 1 | 1.4 ± 1 | 0.917 | 0.8 ± 0 | 0.5 ± 0 | 0.104 | 0.4 ± 0 | 0.2 ± 0 | 0.398 | 0.5 ± 0 | 0.4 ± 0 | 0.978 | ||
| Sex life | 1.5 ± 1 | 1.8 ± 1 | 0.51 | 1.2 ± 1 | 0.8 ± 1 | 0.481 | 0.3 ± 0 | 0.0 ± 0 | 0.362 | 0.2 ± 0 | 0.0 ± 0 | 0.679 | ||
| Social life | 1.7 ± 1 | 2.2 ± 1 | 0.219 | 0.8 ± 1 | 0.8 ± 1 | 0.754 | 0.2 ± 0 | 0.3 ± 0 | 0.627 | 0.2 ± 0 | 0.2 ± 0 | 0.956 | ||
| Traveling | 1.4 ± 1 | 2.8 ± 1 | 1.2 ± 1 | 1.2 ± 1 | 0.894 | 0.3 ± 0 | 0.4 ± 1 | 0.806 | 0.2 ± 0 | 0.1 ± 0 | 0.72 | |||
| COMI | 6.3 ± 2 | 6.8 ± 1 | 0.399 | 4.6 ± 1 | 4.5 ± 1 | 0.803 | 1.5 ± 1 | 1.0 ± 1 | 0.308 | 1.2 ± 1 | 0.7 ± 1 | 0.319 | ||
| BDI | 7.2 ± 5 | 6.9 ± 5 | 0.86 | 4.3 ± 4 | 4.4 ± 4 | 0.938 | 3.3 ± 4 | 4.5 ± 4 | 0.429 | 3.2 ± 3 | 4.6 ± 7 | 0.235 | ||
| PD-Q | 18.4 ± 6 | 16.8 ± 4 | 0.376 | 8.7 ± 6 | 7.4 ± 4 | 0.465 | 5.7 ± 5 | 4.9 ± 4 | 0.644 | 5.8 ± 6 | 5.5 ± 4 | 0.853 | ||
| EQ-5D | 0.85 ± 0.1 | 0.8 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.364 | 0.9 ± 0.1 | 1.0 ± 0.04 | 0.582 | 1.0 ± 0.05 | 1.0 ± 0.04 | 0.543 | |||
Bold entries mark statistically significant results